I Hope Moderna (MRNA) Posts Growth, Says Jim Cramer

Core Insights - Moderna Inc. (NASDAQ:MRNA) has seen its shares increase by 16% over the past year and 31% year-to-date, indicating strong market performance [2] - The company raised its full-year 2025 revenue guidance to $1.9 billion, nearing the high end of the previous estimate of $1.6 billion to $2 billion, during the JPMorgan Healthcare Conference [2] - Moderna also reduced its operating expenses estimate by $200 million and increased its cash balance estimate to $8.1 billion, reflecting improved financial health [2] Analyst Ratings - Jefferies maintained a Hold rating on Moderna's shares with a price target of $30, suggesting a cautious outlook [2] - RBC Capital kept a Sector Perform rating and a price target of $25, highlighting the potential of Moderna's phase three melanoma trial as a key catalyst in 2026 [2] - RBC also noted that optimistic revenue growth guidance and vaccine mandate revisions could present headwinds for the company [2] Jim Cramer's Commentary - Jim Cramer expressed hope for Moderna to achieve its revenue targets, indicating a history of disappointment regarding the company's performance over the past eight years [2][3]